Drug Trial Radar · NCT05134974
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
368
Actual
Start
Nov 18, 2021
Primary completion
Mar 18, 2022
Study completion Mar 29, 2022
Sponsor
- Lead sponsor
- Opus Genetics, IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of this study are: * To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine * To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) * To evaluate the safety of Nyxol * To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis * To evaluate the systemic exposure of Nyxol on pharmacokinetic (PK) sampling
Conditions
- Mydriasis
- Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%Drug
0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Phentolamine Ophthalmic Solution VehicleDrug
Phentolamine Ophthalmic Solution Vehicle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Subjects' Study Eyes With Pupil Diameter Returning to BaselineTime frame: 90 minutes
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site 10
Newport Beach, California
Clinical Site 12
Westminster, California
Clinical Site 9
Delray Beach, Florida
Clinical Site 8
Longwood, Florida
Clinical Site 6
Morrow, Georgia
Clinical Site 1
Roswell, Georgia
Clinical Site 13
Lake Villa, Illinois
Clinical Site 5
Pittsburg, Kansas
Clinical Site 2
Bloomington, Minnesota
Clinical Site 15
Garner, North Carolina
Clinical Site 4
Athens, Ohio
Clinical Site 14
Shrewsbury, Pennsylvania
Clinical Site 7
Warwick, Rhode Island
Clinical Site 11
Sioux Falls, South Dakota
Clinical Site 3
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.